ArticleInternational journal of molecular sciences2026
Cultivating Functional Natural Killer Cells from Mobilized Hematopoietic Stem Cells in Heavily Pretreated Hematologic Malignancies.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
CD19 chimeric antigen receptor (CAR) T cells have demonstrated promising outcomes in B-cell malignancies. However, using pretreated autologous T cells currently faces limitations, including compromised T-cell fitness and the challenge of manufacturing sufficient cell numbers for treatment. Consequently, natural killer (NK) cells have emerged as an alternative due to their natural ability to mediate cytotoxicity and their favorable safety profile. This study aims to generate patient autologous hematopoietic stem cell-derived NK (HSC-NK) cells and assess their therapeutic potential compared to peripheral blood NK (PB-NK) cells. We successfully cultivated HSC-NK under a 28-day, two-step differentiation and expansion protocol, achieving a cumulative 290-fold expansion using optimized memory-like cytokines and feeder cell stimulation. The expanded HSC-NK cells demonstrated a distinct phenotype (CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.